1039037-04-1

Basic information

• Product Name: ethyl 2-(1H-benzotriazol-1-yloxy)-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyano-nicotinate
• Synonyms: ethyl 2-(1H-benzotriazol-1-yloxy)-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyano-nicotinate
• CAS NO: 1039037-04-1
• Molecular Weight: 589.632
• Mol File: 1039037-04-1.mol

Chemical Properties

• CAS DataBase Reference: ethyl 2-(1H-benzotriazol-1-yloxy)-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyano-nicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(1H-benzotriazol-1-yloxy)-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyano-nicotinate(1039037-04-1)
• EPA Substance Registry System: ethyl 2-(1H-benzotriazol-1-yloxy)-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyano-nicotinate(1039037-04-1)

Safety Data

• Hazardous Substances Data: 1039037-04-1(Hazardous Substances Data)

Upstream product

• 1039037-03-0 1-[3-cyano-5-(ethoxycarbonyl)-6-{[(trifluoromethyl)sulfonyl]oxy}pyridin-2-yl]piperidine-4-carboxylic acid 
• 4563-33-1 phenyl-methanesulfonic acid amide 
• 125700-67-6 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 

Downstream Products

• 1039068-25-1 ethyl 6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyano-2-(methylthio)nicotinate 
• 1039036-71-9 ethyl 6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyano-2-[(2-isopropoxy-2-oxoethyl)thio]nicotinate 
• 1039035-70-5 {[6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyano-3-(ethoxycarbonyl)pyridin-2-yl]thio}acetic acid 

Relevant articles and documents

New Pyridine Analogues IX 519

The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.

NEW PYRIDINE ANALOGUES VIII 518

The present invention relates to certain new pyridin analogues of Formula ( I ) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.